Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-248 in Mature B-cell Malignancies
NCT05728658Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Mar 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesutoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 4 more, sponsored by InnoCare Pharma. Primary endpoints: Maximum Tolerated Dose at 5 years, Recommended Phase 2 Dose at 5 years and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
mesutoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05728658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728658.